Eli Lilly will be presenting data from studies on multiple GLP-1 drugs later this month. Eli Lilly (NYSE: LLY) stock hasn't ...

Eli Lilly’s LLY key top-line drivers are its GLP-1 medicines, Mounjaro for type II diabetes and Zepbound for obesity. Both ...

The Japanese biotech behind Eli Lilly’s new blockbuster obesity pill believes it could be used with an anti-muscle wasting ...

Eli Lilly’s diabetes and obesity management drug Mounjaro saw a sharp rise in sales for the third consecutive month, driven ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Eli Lilly's (LLY) sees a 60% sales jump from April to May in India for its obesity/ diabetes drug Mounjaro. Read more here.

The US drugmaker sold ₹12.6 crore ($1.5 million) worth of the injections last month, according to market analysis firm ...

A new study shows weight-loss drugs, such as Novo Nordisk's Wegovy and Eli Lilly's Mounjaro, yield lower weight reductions in ...

Eli Lilly's weight-loss and diabetes drug, Mounjaro, has experienced a 60% sales increase in India between April and May.

Eli Lilly (NYSE: LLY) sells a broad range of medicines, from cancer and immunology drugs to treatments for migraine. Right ...

Eli Lilly & Co. increased sales of weight-loss and diabetes drug Mounjaro 60% in India in May from April in its second full ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...